Incretin Mimetics and Amylin Analogues

Nisha K. Patel, Pharm.D., Emily Pherson, Pharm.D., Brian Pinto, Pharm.D., Ana Emiliano, M.D.

Incretin Mimetics and Amylin Analogues is a topic covered in the Johns Hopkins Diabetes Guide.

To view the entire topic, please log in or purchase a subscription.

Official website of the Johns Hopkins Antibiotic (ABX), HIV, Diabetes, and Psychiatry Guides, powered by Unbound Medicine. Johns Hopkins Guide App for iOS, iPhone, iPad, and Android included. Explore these free sample topics:

Monkeypox

Coronavirus COVID-19 (SARS-CoV-2)

Suicide Risk in the COVID-19 Pandemic

Moderna COVID-19 Vaccine

BNT162b2 COVID-19 Vaccine (BioNTech/Pfizer)

Managing Stress and Coping with COVID-19

Johnson & Johnson COVID-19 Vaccine

-- The first section of this topic is shown below --

INDICATIONS

FDA

Incretin mimetics also knownn as GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, semaglutide and dulaglutide): type 2 diabetes (T2DM), although insufficient data to support use in conjunction with prandial insulin.
- High-dose liraglutide (Saxenda™) and semaglutide (Wegovy™): chronic weight management, adjunct to a reduced-calorie diet and increased physical activity in adult patients with an initial body mass index of 30 kg/m² or greater (obese) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. T2DM, hypertension, dyslipidemia)
Amylin analogues (pramlintide): type 1 diabetes (T1DM) or T2DM on insulin therapy.

-- To view the remaining sections of this topic, please log in or purchase a subscription --

INDICATIONS

FDA

Incretin mimetics also knownn as GLP-1 receptor agonists (exenatide, liraglutide, lixisenatide, semaglutide and dulaglutide): type 2 diabetes (T2DM), although insufficient data to support use in conjunction with prandial insulin.
- High-dose liraglutide (Saxenda™) and semaglutide (Wegovy™): chronic weight management, adjunct to a reduced-calorie diet and increased physical activity in adult patients with an initial body mass index of 30 kg/m² or greater (obese) or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g. T2DM, hypertension, dyslipidemia)
Amylin analogues (pramlintide): type 1 diabetes (T1DM) or T2DM on insulin therapy.

There's more to see -- the rest of this entry is available only to subscribers.